ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,401 to 4,420 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Prior CD Decision App (PCDDA) vs Usual Care - No App: 3rd or 4th Degree Lacerations16 of 720

12 of 723

0.6 points

-0.9 to 2.1

1,443NCT02646423

Effect of a Patient-Centered Decision App on TOLAC

Prior CD Decision App (PCDDA) vs Usual Care - No App: Maternal Major Morbidity19 of 720

23 of 723

-0.5 points

-2.4 to 1.2

1,443NCT02646423

Effect of a Patient-Centered Decision App on TOLAC

Prior CD Decision App (PCDDA) vs Usual Care - No App: Neonatal Intensive Care Unit (NICU) Admission98 of 720

87 of 722

1.6 points

-1.9 to 5.0

1,442NCT02646423

Effect of a Patient-Centered Decision App on TOLAC

Total Hip Arthroplasty vs Hemi-arthroplasty: deaths from any cause103 of 718

95 of 723

1.2 points

-2.4 to 4.8

1,441NCT00556842

Comparing Total Hip Arthroplasty and Hemi-Arthroplasty on Secondary Procedures and Quality of Life in Adults With Displaced Hip Fractures

Total Hip Arthroplasty vs Hemiarthroplasty: Number of Participants With Functional Mobility Problems210 of 718

206 of 723

0.8 points

-3.9 to 5.4

1,441NCT00556842

Comparing Total Hip Arthroplasty and Hemi-Arthroplasty on Secondary Procedures and Quality of Life in Adults With Displaced Hip Fractures

Total Hip Arthroplasty vs Hemi-arthroplasty: Number of Participants With Revision Surgery57 of 718

60 of 723

-0.4 points

-3.2 to 2.5

1,441NCT00556842

Comparing Total Hip Arthroplasty and Hemi-Arthroplasty on Secondary Procedures and Quality of Life in Adults With Displaced Hip Fractures

Total Hip Arthroplasty vs Hemi-arthroplasty: serious adverse events300 of 718

265 of 723

5.1 points

0.1 to 10.1

1,441NCT00556842

Comparing Total Hip Arthroplasty and Hemi-Arthroplasty on Secondary Procedures and Quality of Life in Adults With Displaced Hip Fractures

EP2006: Any CIN/FN-related Chemotherapy Disturbance vs EP2006: No CIN/FN-related Chemotherapy Disturbance: Number of Participants With Cancer-related Mortality by Any CIN/FN-related Chemotherapy Disturbance2 of 138

33 of 1,303

-1.1 points

-2.5 to 2.7

1,441NCT01459653

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

EP2006: Any Grade 4 CIN/FN vs EP2006: No Grade 4 CIN/FN: Number of Participants With Cancer-related Mortality by Any/no Grade 4 CIN or FN6 of 221

29 of 1,220

0.3 points

-1.4 to 3.5

1,441NCT01459653

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Prior CD Decision App (PCDDA) vs Usual Care - No App: Maternal Minor Morbidity36 of 719

36 of 722

0.0 points

-2.3 to 2.3

1,441NCT02646423

Effect of a Patient-Centered Decision App on TOLAC

Regimen A vs Regimen B: serious adverse events10 of 112

785 of 1,328

-50.2 points

-55.0 to -42.9

1,440NCT00026312

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Subcutaneous Abatacept vs Intravenous Abatacept: Double-blind Period: Number of Participants Achieving Clinically Meaningful HAQ-DI Response at Day 169483 of 729

442 of 711

4.1 points

-0.9 to 9.0

1,440NCT00559585

Methotrexate-Inadequate Response Study

Prior CD Decision App (PCDDA) vs Usual Care - No App: Neonatal Respiratory Morbidity67 of 719

68 of 721

-0.1 points

-3.1 to 2.9

1,440NCT02646423

Effect of a Patient-Centered Decision App on TOLAC

Hyperinsulinemic-normoglycemic Clamp vs Insulin at the Standard of Care Levels: Any Major Morbidity/30-day Mortality46 of 709

82 of 730

-4.7 points

-7.7 to -1.8

1,439NCT00524472

Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery

Hyperinsulinemic-normoglycemic Clamp vs Insulin at the Standard of Care Levels: Post Operative Atrial Fibrillation209 of 709

235 of 730

-2.7 points

-7.5 to 2.1

1,439NCT00524472

Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery

Hyperinsulinemic-normoglycemic Clamp vs Insulin at the Standard of Care Levels: a Composite of Minor Postoperative Complications200 of 709

237 of 730

-4.3 points

-9.0 to 0.5

1,439NCT00524472

Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery

Hyperinsulinemic-normoglycemic Clamp vs Insulin at the Standard of Care Levels: deaths from any cause32 of 709

22 of 730

1.5 points

-0.5 to 3.6

1,439NCT00524472

Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery

Hyperinsulinemic-normoglycemic Clamp vs Insulin at the Standard of Care Levels: serious adverse events18 of 709

27 of 730

-1.2 points

-3.0 to 0.7

1,439NCT00524472

Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery

Drug Users vs Non-drug Users: The Prevalence of Superficial and Cutaneous Fungal Infections Among Drug and Non-Drug Users73 of 718

62 of 718

1.5 points

-1.5 to 4.6

1,436NCT02681458

Superficial and Cutaneous Fungal Infections Among Drug-users in Northeast Region of Iran

Distress Screening vs No Screening: Number of Participants Offered and Screened for Distress596 of 744

3 of 692

79.7 points

76.5 to 82.4

1,436NCT02941614

Implementing Systematic Distress Screening in Breast Cancer

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=221"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=221

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02646423-1b635b2c",
        "title": "Prior CD Decision App (PCDDA) vs Usual Care - No App: 3rd or 4th Degree Lacerations",
        "summary": "16 of 720 against 12 of 723; risk difference 0.6 points, 95% interval -0.9 to 2.1; NCT02646423, Effect of a Patient-Centered Decision App on TOLAC",
        "record": "/library/comparisons/NCT02646423-1b635b2c",
        "nct_id": "NCT02646423",
        "kind": "outcome",
        "participants": 1443,
        "risk_difference": {
          "value": 0.00562471184877824,
          "lower": -0.009233205775438229,
          "upper": 0.020929080954219855
        },
        "group_1": "16 of 720",
        "group_2": "12 of 723",
        "difference": "0.6 points",
        "interval": "-0.9 to 2.1",
        "trial_title": "Effect of a Patient-Centered Decision App on TOLAC"
      },
      {
        "id": "NCT02646423-45065188",
        "title": "Prior CD Decision App (PCDDA) vs Usual Care - No App: Maternal Major Morbidity",
        "summary": "19 of 720 against 23 of 723; risk difference -0.5 points, 95% interval -2.4 to 1.2; NCT02646423, Effect of a Patient-Centered Decision App on TOLAC",
        "record": "/library/comparisons/NCT02646423-45065188",
        "nct_id": "NCT02646423",
        "kind": "outcome",
        "participants": 1443,
        "risk_difference": {
          "value": -0.005423005993545411,
          "lower": -0.023541704636688515,
          "upper": 0.012458285505082073
        },
        "group_1": "19 of 720",
        "group_2": "23 of 723",
        "difference": "-0.5 points",
        "interval": "-2.4 to 1.2",
        "trial_title": "Effect of a Patient-Centered Decision App on TOLAC"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=222",
  "request_id": "KXwgErVnOjBZ1rk4"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?